Evidence map›Paper›PMID 26956206›Full record

ArticleStem cells translational medicine2016

Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance.

Maria Laura De Angelis, Ann Zeuner, Eleonora Policicchio, Giorgio Russo, Alessandro Bruselles, Michele Signore, Sara Vitale, Gabriele De Luca, Emanuela Pilozzi, Alessandra Boe and 8 more

Open access · goldAbstract read
In one paragraph

Article in Stem cells translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. The Impact of Cancer Stem Cells in Colorectal Cancer.International journal of molecular sciences · 2024
    Review
  9. Cell Therapy as Target Therapy against Colon Cancer Stem Cells.International journal of molecular sciences · 2023
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Maria Laura De AngelisDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Ann ZeunerDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Eleonora PolicicchioDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy Department of Experimental Medicine, Università "La Sapienza," Rome, Italy.
Giorgio RussoDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy Istituto Nazionale Tumori Regina Elena, Rome, Italy.
Alessandro BrusellesDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Michele SignoreDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Sara VitaleDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy Istituto Nazionale Tumori Regina Elena, Rome, Italy.
Gabriele De LucaDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Emanuela PilozziDepartment of Clinical and Molecular Medicine, Ospedale S. Andrea, Università "La Sapienza," Rome, Italy.
Alessandra BoeDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Giorgio StassiDepartment of Surgical and Oncological Sciences, Università di Palermo, Palermo, Italy.
Lucia Ricci-VitianiDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Carla Azzurra AmoreoIstituto Nazionale Tumori Regina Elena, Rome, Italy.
Alfredo PagliucaDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Federica FrancescangeliDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy Istituto Nazionale Tumori Regina Elena, Rome, Italy.
Marco TartagliaDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy Ospedale Pediatrico Bambino Gesù, Rome, Italy.
Ruggero De MariaIstituto Nazionale Tumori Regina Elena, Rome, Italy marta.baiocchi@iss.it demaria@ifo.it.
Marta BaiocchiDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy marta.baiocchi@iss.it demaria@ifo.it.
Istituto Superiore di Sanità · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITInstituto Nazionale Tumori Regina ElenaAzienda Ospedaliera Sant'Andrea · ITUniversity of Palermo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledColorectal cancer (CRC) therapy mainly relies on the use of conventional chemotherapeutic drugs combined, in a subset of patients, with epidermal growth factor receptor [EGFR]-targeting agents. Although CRC is considered a prototype of a cancer stem cell (CSC)-driven tumor, the effects of both conventional and targeted therapies on the CSC compartment are largely unknown. We have optimized a protocol for colorectal CSC isolation that allowed us to obtain CSC-enriched cultures from primary tumor specimens, with high efficiency. CSC isolation was followed by in vitro and in vivo validation, genetic characterization, and drug sensitivity analysis, thus generating panels of CSC lines with defined patterns of genetic mutations and therapy sensitivity. Colorectal CSC lines were polyclonal and maintained intratumor heterogeneity in terms of somatically acquired mutations and differentiation state. Such CSC-enriched cultures were used to investigate the effects of both conventional and targeted therapies on the CSC compartment in vivo and to generate a proteomic picture of signaling pathways implicated in sensitivity/resistance to anti-EGFR agents. We propose CSC lines as a sound preclinical framework to test the effects of therapies in vitro and in vivo and to identify novel determinants of therapy resistance. SIGNIFICANCE: Colorectal cancer stem cells (CSCs) have been shown to be responsible for tumor propagation, metastatic dissemination, and relapse. However, molecular pathways present in CSCs, as well as mechanisms of therapy resistance, are mostly unknown. Taking advantage of genetically characterized CSC lines derived from colorectal tumors, this study provides an extensive analysis of CSC response to EGFR-targeted therapy in vivo and an overview of factors implicated in therapy response or resistance. Furthermore, the implementation of a biobank of molecularly annotated CSC lines provides an innovative resource for future investigations in colorectal cancer.

Indexed as

AnimalsCells, CulturedColorectal NeoplasmsDrug Resistance, NeoplasmFemaleGene Expression ProfilingHumansMice, Inbred NODMice, SCIDMice, TransgenicMicroarray AnalysisModels, BiologicalNeoplastic Stem CellsProtein Kinase InhibitorsProteomicsSignal TransductionProtein Kinase InhibitorsAnti-EGFR therapyCancer stem cellsCetuximabColorectal cancerProteomic arrays

Identifiers

PMID26956206
PMCPMC4798739
OpenAlexW2295718866

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.